Evidence That Serum Levels of the Soluble Receptor for Advanced Glycation End Products Are Inversely Associated with Pancreatic Cancer Risk: A Prospective Study

被引:64
|
作者
Jiao, Li [1 ]
Weinstein, Stephanie J. [1 ]
Albanes, Demetrius [1 ]
Taylor, Philip R. [1 ]
Graubard, Barry I. [1 ]
Virtamo, Jarmo [2 ]
Stolzenberg-Solomon, Rachael Z. [1 ]
机构
[1] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[2] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland
关键词
RAGE LIGANDS; FORM SRAGE; DISEASE; AGE; INFLAMMATION; ENDPRODUCTS; EXPRESSION; BIOMARKERS; INSULIN; HEALTH;
D O I
10.1158/0008-5472.CAN-10-2573
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cigarette smoking, obesity, type 2 diabetes, and, to a lesser extent, meat cooked at high temperatures are associated with pancreatic cancer. Cigarette smoke and foods cooked at higher temperatures are major environmental sources of advanced glycation end products (AGE). AGEs accumulate during hyperglycemia and elicit oxidative stress and inflammation through interaction with the receptor for AGEs (RAGE). Soluble RAGE (sRAGE) acts as an anti-inflammatory factor to neutralize AGEs and block the effects mediated by RAGE. In this study, we investigated the associations of prediagnostic measures of N-epsilon-(carboxymethyl)-lysine (CML)-AGE and sRAGE with pancreatic cancer in a case-cohort study within a cohort of 29,133 Finnish male smokers. Serum samples and exposure information were collected at baseline (1985-1988). We measured CML-AGE, sRAGE, glucose, and insulin concentrations in fasting serum from 255 incident pancreatic cancer cases that arose through April 2005 and from 485 randomly sampled subcohort participants. Weighted Cox proportional hazard regression models were used to calculate relative risks (RR) and 95% CI, adjusted for age, years of smoking, and body mass index. CML-AGE and sRAGE were mutually adjusted. CML-AGE levels were not associated with pancreatic cancer [fifth compared with first quintile, RR (95% CI): 0.68 (0.38-1.22), P-trend -0.27]. In contrast, sRAGE levels were inversely associated with pancreatic cancer [fifth compared with first quintile, RR (95% CI): 0.46 (0.23-0.73), P-trend = 0.002]. Further adjustment for glucose or insulin levels did not change the observed associations. Our findings suggest that sRAGE is inversely associated with pancreatic cancer risk among Finnish male smokers. Cancer Res; 71(10); 3582-9. (C) 2011 AACR.
引用
收藏
页码:3582 / 3589
页数:8
相关论文
共 50 条
  • [1] Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products and Risk of Colorectal Cancer - A Prospective Cohort Study
    Jiao, Li
    Albanes, Demetrius
    Weinstein, Stephanie J.
    Graubard, Barry I.
    Taylor, Philip R.
    Virtamo, Jarmo
    Stolzenberg-Solomon, Rachael
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S18 - S18
  • [2] A prospective study of soluble receptor for advanced glycation end products and adiponectin and pancreatic cancer in postmenopausal women
    White, Donna L.
    Hoogeveen, Ron
    Royse, Kathryn
    Chen, Liang
    Tinker, Lesley
    Rohan, Tom
    Whitsel, Eric
    El-Serag, Hashem B.
    Jiao, Li
    [J]. CANCER RESEARCH, 2016, 76
  • [3] Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer
    Jiao, Li
    Taylor, Philip R.
    Weinstein, Stephanie J.
    Graubard, Barry I.
    Virtamo, Jarmo
    Albanes, Demetrius
    Stolzenberg-Solomon, Rachael Z.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (07) : 1430 - 1438
  • [4] ADVANCED GLYCATION END PRODUCTS, SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND RISK OF LIVER CANCER.
    Moy, K. A.
    Jiao, L.
    Freedman, N. D.
    Weinstein, S. J.
    Sinha, R.
    Virtamo, J.
    Albanes, D.
    Stolzenberg-Solomon, R. Z.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 : S103 - S103
  • [5] A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women
    White, Donna L.
    Hoogeveen, Ron C.
    Chen, Liang
    Richardson, Peter
    Ravishankar, Milan
    Shah, Preksha
    Tinker, Lesley
    Rohan, Thomas
    Whitsel, Eric A.
    Ei-Serag, Hashem B.
    Jiao, Li
    [J]. CANCER MEDICINE, 2018, 7 (05): : 2180 - 2191
  • [6] Soluble receptor for advanced glycation end products and risk of liver cancer
    Moy, Kristin A.
    Jiao, Li
    Freedman, Neal D.
    Weinstein, Stephanie J.
    Sinha, Rashmi
    Virtamo, Jarmo
    Albanes, Demetrius
    Stolzenberg-Solomon, Rachael Z.
    [J]. HEPATOLOGY, 2013, 57 (06) : 2338 - 2345
  • [7] A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women
    Chen, Liang
    Duan, Zhigang
    Tinker, Lesley
    Sangi-Haghpeykar, Haleh
    Strickler, Howard
    Ho, Gloria Y. F.
    Gunter, Marc J.
    Rohan, Thomas
    Logsdon, Craig
    White, Donna L.
    Royse, Kathryn
    El-Serag, Hashem B.
    Jiaoa, Li
    [J]. CANCER EPIDEMIOLOGY, 2016, 42 : 115 - 123
  • [8] Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults
    Davis, Kathleen E.
    Prasad, Chandan
    Vijayagopal, Parakat
    Juma, Shanil
    Imrhan, Victorine
    [J]. NUTRITION RESEARCH, 2014, 34 (06) : 478 - 485
  • [9] Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetes
    Tan, K. C. B.
    Chow, W. S.
    Shiu, S. W. M.
    Bucala, R.
    Betteridge, D. J.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 294 - 294
  • [10] Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects
    Yamagishi, Sho-ichi
    Adachi, Hisashi
    Nakamura, Kazuo
    Matsui, Takanori
    Jinnouchi, Yuko
    Takenaka, Katsuhiko
    Takeuchi, Masayoshi
    Enomoto, Mika
    Furuki, Kumiko
    Hino, Asuka
    Shigeto, Yoshiyuki
    Imaizumi, Tsutomu
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (09): : 1227 - 1231